GO:0046473 phosphatidic acid metabolic process

Phosphatidic acid (PA) is a simple glycerophospholipid that serves as both a biosynthetic intermediate and a dynamic signaling molecule. The Gene Ontology term GO:0046473, phosphatidic acid metabolic process, encompasses the chemical reactions and pathways involving PA, including its synthesis, interconversion, and degradation. PA is produced primarily through the acylation of lysophosphatidic acid by LPAAT enzymes and through the hydrolysis of phosphatidylcholine by phospholipase D (PLD). It is also generated by diacylglycerol kinases (DGKs), which phosphorylate diacylglycerol to yield PA. Conversely, PA is consumed by phosphatidic acid phosphatases (PAPs/LPINs) and by enzymes that convert it to CDP-diacylglycerol or other lipids. This metabolic network is highly conserved and essential for membrane biogenesis, lipid storage, and signal transduction. Beyond its structural role, PA acts as a lipid second messenger that recruits and activates diverse effector proteins, including kinases, phosphatases, and GTPase-activating proteins. Through these interactions, PA regulates processes such as cell proliferation, cytoskeletal dynamics, vesicle trafficking, and immune responses. In the nervous system, PA signaling influences synaptic vesicle cycling and neurotransmission. In plants, PA bursts are critical for reactive oxygen species (ROS) production during immunity. Recent work has also revealed that PA homeostasis at the inner nuclear membrane is governed by seipin, linking PA metabolism to nuclear architecture and lipid droplet biology. Given its central role in lipid metabolism and signaling, the phosphatidic acid metabolic process is a focal point for researchers in cell biology, neuroscience, immunology, and cancer. Understanding how PA levels are controlled and how they transmit signals requires precise genetic tools. This article provides a research-grade overview of GO:0046473, covering its definition, key genes, regulatory mechanisms, disease relevance, and the CRISPR-based methods used to study it.

GO:0046473 phosphatidic acid metabolic process is defined as the chemical reactions and pathways involving phosphatidic acid, any derivative of glycerol phosphate in which both the remaining hydroxyl groups of the glycerol moiety are esterified with fatty acids. This includes the biosynthesis of PA from lysophosphatidic acid or diacylglycerol, the conversion of PA to diacylglycerol or CDP-diacylglycerol, and the signaling events mediated by PA itself.

The phosphatidic acid metabolic process is fundamentally important because PA sits at the crossroads of lipid biosynthesis and signal transduction. It is required for the production of major membrane lipids and storage fats, and it acts as a spatiotemporal signal that controls cell growth, motility, and immune responses. Dysregulation of PA metabolism contributes to cancer progression, neurodegeneration, and metabolic diseases, making its enzymes attractive drug targets. Moreover, PA metabolism is conserved from plants to humans, and its study informs agriculture and medicine alike.

The following genes encode enzymes and regulators that directly participate in or control the phosphatidic acid metabolic process.

Phosphatidic acid metabolic process is regulated at multiple levels. Enzymes such as PLD, DGK, and PAP are controlled by phosphorylation, calcium, and lipid interactions. For example, DGK-theta is regulated by phosphorylation and membrane recruitment, affecting PA production in neurons. In plants, DGK5 dual phosphorylation controls PA burst and ROS production during immunity. Seipin regulates PA homeostasis at the inner nuclear membrane, influencing lipid droplet formation. Additionally, PA levels are sensed by feedback mechanisms involving mTOR and other kinases, which in turn modulate lipid synthesis. This intricate regulation ensures that PA signals are transient and spatially confined.

PA metabolic enzymes are frequently dysregulated in cancer. PLD and DGK isoforms promote tumor cell proliferation, survival, and migration through PA-mediated activation of mTOR, Raf-1, and other oncogenic pathways. Elevated PLD activity has been observed in several cancers, and DGK inhibition reduces tumor growth in preclinical models. Targeting PA metabolism is therefore a promising therapeutic strategy.

PA signaling is critical for synaptic vesicle cycling and neurotransmission. DGK-theta and PLD regulate synaptic function, and their dysfunction has been linked to neurodegenerative conditions. PA also influences mitochondrial dynamics, which are impaired in Parkinson's and Alzheimer's diseases. Modulating PA metabolism may offer neuroprotective benefits.

LPIN1 mutations cause severe metabolic disorders, including recurrent rhabdomyolysis and lipodystrophy. Seipin (BSCL2) mutations lead to congenital generalized lipodystrophy, highlighting the role of PA homeostasis in lipid storage and nuclear envelope function. These findings underscore the importance of PA metabolism in metabolic health.

PA is a key mediator of immune signaling. In plants, DGK5-mediated PA burst is required for ROS production and immunity. In mammals, PA regulates T-cell activation and inflammatory responses through DGK and PLD pathways. Dysregulated PA metabolism contributes to autoimmune and inflammatory diseases.

Mass spectrometry-based lipidomics enables quantitative profiling of PA species and other lipids in cells and tissues. This method is essential for measuring changes in PA levels upon genetic or pharmacological perturbation.

Genetically encoded PA biosensors, such as GFP-tagged PA-binding domains, allow real-time visualization of PA production at specific membranes. This approach has been used to track PA bursts during plant immunity and synaptic activity.

Genome-wide CRISPR knockout screens can identify genes that regulate PA metabolism and PA-dependent phenotypes. Such screens are powerful for discovering novel regulators and drug targets.

In vitro assays measuring PLD, DGK, and PAP activities provide direct readouts of enzyme function and are used to validate inhibitors and mutations. These assays often use radiolabeled or fluorescent substrates.

Researchers studying phosphatidic acid metabolic process-related genes often need to determine whether a candidate gene is causally involved in PA production, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell and animal models, enabling rigorous functional validation.

The phosphatidic acid metabolic process (GO:0046473) is a fundamental biological process that bridges lipid biosynthesis and signal transduction. Its enzymes and effectors are implicated in a wide range of human diseases, from cancer to neurodegeneration and metabolic disorders. Understanding the precise regulation of PA metabolism requires advanced genetic tools. CRISPR-based knockout, point mutation, knock-in, and overexpression models, combined with lipidomics and imaging, provide the necessary resolution to dissect this pathway. As research advances, targeting PA metabolism may yield novel therapeutic strategies for multiple diseases.